Related Experiment Video
Updated: Oct 23, 2025

Intra-tracheal Administration of Haemophilus influenzae in Mouse Models to Study Airway Inflammation
Published on: March 2, 2016
Contribution of dipeptidyl peptidase 4 to non-typeable Haemophilus influenzae-induced lung inflammation in COPD
Sudhir Kotnala1, Yerin Kim1, Charu Rajput1
1Department of Thoracic Surgery and Medicine, Temple University School of Medicine, Philadelphia, PA 16140, United States.
Abstract:
Dipeptidyl peptidase 4 (DPP4) expression is increased in the lungs of chronic obstructive pulmonary disease (COPD). DPP4 is known to be associated with inflammation in various organs, including LPS-induced acute lung inflammation. Since non-typeable Haemophilus influenzae (NTHi) causes acute exacerbations in COPD patients, we examined the contribution of DPP4 in NTHi-induced lung inflammation in COPD. Pulmonary macrophages isolated from COPD patients showed higher expression of DPP4 than the macrophages isolated from normal subjects. In response to NTHi infection, COPD, but not normal macrophages show a further increase in the expression of DPP4. COPD macrophages also showed higher expression of IL-1β, and CCL3 responses to NTHi than normal, and treatment with DPP4 inhibitor, diprotin A attenuated this response. To examine the contribution of DPP4 in NTHi-induced lung inflammation, COPD mice were infected with NTHi, treated with diprotin A or PBS intraperitoneally, and examined for DPP4 expression, lung inflammation, and cytokine expression. Mice with COPD phenotype showed increased expression of DPP4, which increased further following NTHi infection. DPP4 expression was primarily observed in the infiltrated inflammatory cells. NTHi-infected COPD mice also showed sustained neutrophilic lung inflammation and expression of CCL3, and this was inhibited by DPP4 inhibitor. These observations indicate that enhanced expression of DPP4 in pulmonary macrophages may contribute to sustained lung inflammation in COPD following NTHi infection. Therefore, inhibition of DPP4 may reduce the severity of NTHi-induced lung inflammation in COPD.
Insights
Enhanced dipeptidyl peptidase 4 (DPP4) expression in chronic obstructive pulmonary disease (COPD) lungs drives inflammation. DPP4 inhibition reduced lung inflammation in COPD mice infected with non-typeable Haemophilus influenzae (NTHi).
Area of Science:
- Pulmonary immunology
- Inflammatory diseases
- Microbial pathogenesis
Background:
- Dipeptidyl peptidase 4 (DPP4) expression is elevated in chronic obstructive pulmonary disease (COPD) lungs.
- DPP4 is implicated in inflammation, including lipopolysaccharide-induced acute lung injury.
- Non-typeable Haemophilus influenzae (NTHi) is a common cause of COPD exacerbations.
Purpose of the Study:
- To investigate the role of DPP4 in NTHi-induced lung inflammation in COPD.
- To evaluate the therapeutic potential of DPP4 inhibition in NTHi-infected COPD models.
Main Methods:
- Pulmonary macrophages from COPD patients and healthy subjects were analyzed for DPP4 expression and inflammatory responses to NTHi.
- A mouse model of COPD was infected with NTHi, and treated with a DPP4 inhibitor (diprotin A) or placebo.
- Lung inflammation, DPP4 expression, and cytokine levels (IL-1β, CCL3) were assessed in both in vitro and in vivo models.
Main Results:
- COPD macrophages exhibited higher baseline DPP4 expression and increased DPP4, IL-1β, and CCL3 responses to NTHi compared to normal macrophages.
- DPP4 inhibition with diprotin A attenuated these inflammatory responses in COPD macrophages.
- NTHi-infected COPD mice showed increased DPP4 expression, sustained neutrophilic lung inflammation, and elevated CCL3 levels, all of which were reduced by diprotin A treatment.
Conclusions:
- Elevated DPP4 expression in pulmonary macrophages contributes to sustained lung inflammation in COPD following NTHi infection.
- DPP4 inhibition represents a potential therapeutic strategy to mitigate the severity of NTHi-induced lung inflammation in COPD patients.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pneumonia II: Pathophysiology
Dipeptidyl Peptidase 4 Inhibitors

